NASDAQ:ACXP Acurx Pharmaceuticals (ACXP) Stock Price, News & Analysis $1.15 -0.05 (-4.17%) Closing price 10/14/2026 04:00 PM EasternExtended Trading$1.20 +0.05 (+4.26%) As of 04:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC Filings About Acurx Pharmaceuticals Stock (NASDAQ:ACXP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Acurx Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.15▼$1.2250-Day Range$1.15▼$1.6552-Week Range$1.15▼$7.81Volume80,827 shsAverage Volume94,363 shsMarket Capitalization$6.39 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) is a clinical-stage biopharmaceutical company focused on developing novel antibiotics for serious bacterial infections. The company’s research is centered on antibacterial compounds designed to address pathogens that are increasingly resistant to existing treatments. Acurx’s lead product candidate is ibezapolstat, an investigational antibiotic being developed for the treatment of Clostridioides difficile infection, commonly known as C. difficile or C. diff infection. Ibezapolstat is designed to work through a differentiated mechanism that targets bacterial DNA polymerase IIIC, an enzyme involved in bacterial DNA replication. The company has also evaluated the compound’s potential effects on the gut microbiome, which may be relevant to the recurrence of C. difficile infection. Acurx does not have marketed products and is focused on advancing its pipeline through clinical development and regulatory evaluation. Its activities are primarily directed toward the United States and other markets where its clinical and regulatory programs are conducted. As a development-stage company, Acurx’s future prospects depend on the results of clinical trials, regulatory approvals and its ability to obtain funding or strategic support for continued development.AI Generated. May Contain Errors. Read More Acurx Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreACXP MarketRank™: 1.98250920568 of 5 starsAcurx Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.4 / 5Analyst RatingHold Consensus RatingAcurx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAcurx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Acurx Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Acurx Pharmaceuticals are expected to grow in the coming year, from ($2.00) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Acurx Pharmaceuticals is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Acurx Pharmaceuticals is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAcurx Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Acurx Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.15% of the float of Acurx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAcurx Pharmaceuticals has a short interest ratio ("days to cover") of 1.02, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Acurx Pharmaceuticals has recently decreased by 9.96%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAcurx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAcurx Pharmaceuticals does not have a long track record of dividend growth. News and Social Media4.3 / 5News SentimentN/A News SentimentAcurx Pharmaceuticals has a news sentiment score of 1.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Acurx Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest1 people have searched for ACXP on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Acurx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Acurx Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders6.50% of the stock of Acurx Pharmaceuticals is held by insiders.Percentage Held by Institutions11.53% of the stock of Acurx Pharmaceuticals is held by institutions.Read more about Acurx Pharmaceuticals' insider trading history. Receive ACXP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acurx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACXP Stock News HeadlinesAcurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The StreetOctober 5, 2026 | finance.yahoo.comAcurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile InfectionSeptember 29, 2026 | prnewswire.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs.September 14, 2026 | prnewswire.comAnalysts Offer Insights on Healthcare Companies: Annovis Bio (ANVS) and Acurx Pharmaceuticals (ACXP)August 21, 2026 | theglobeandmail.comAcurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for IbezapolstatAugust 17, 2026 | prnewswire.comAcurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings Call TranscriptAugust 14, 2026 | seekingalpha.comAcurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business updateAugust 14, 2026 | prnewswire.comSee More Headlines ACXP Stock Analysis - Frequently Asked Questions How have ACXP shares performed this year? Acurx Pharmaceuticals' stock was trading at $2.49 on January 1st, 2026. Since then, ACXP shares have decreased by 53.8% and is now trading at $1.15. How were Acurx Pharmaceuticals' earnings last quarter? Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) posted its earnings results on Thursday, August, 13th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.15. Read the conference call transcript. When did Acurx Pharmaceuticals' stock split? Acurx Pharmaceuticals shares reverse split before market open on Tuesday, August 5th 2025.A 1-20 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Acurx Pharmaceuticals IPO? Acurx Pharmaceuticals (ACXP) raised $15 million in an initial public offering on Friday, June 25th 2021. The company issued 2,500,000 shares at a price of $5.00-$7.00 per share. Alexander Capital, L.P. and Network 1 Financial Securities served as the underwriters for the IPO. How do I buy shares of Acurx Pharmaceuticals? Shares of ACXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Acurx Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acurx Pharmaceuticals investors own include Alphabet (GOOG), Tesla (TSLA), Amprius Technologies (AMPX), iShares Silver Trust (SLV), Advanced Micro Devices (AMD), Applied Digital (APLD) and CrowdStrike (CRWD). Company Calendar Last Earnings8/13/2026Today10/15/2026AGM 202610/16/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ACXP's financial health is in the Red zone, according to TradeSmith. ACXP has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ACXP CIK1736243 Webwww.acurxpharma.com Phone917-533-1469FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.97 million Net MarginsN/A Pretax MarginN/A Return on Equity-124.73% Return on Assets-87.48% Debt Debt-to-Equity RatioN/A Current Ratio3.88 Quick Ratio3.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.07 per share Price / Book0.56Miscellaneous Outstanding Shares5,560,000Free Float5,198,000Market Cap$6.39 million OptionableNo Data Beta-2.05 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ACXP) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acurx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acurx Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
